Cantor Fitzgerald Maintains Neutral on Health Catalyst, Lowers Price Target to $3
Benzinga Newsdesk 8 months ago
NewsPrice TargetAnalyst Ratings
Cantor Fitzgerald analyst Sarah James maintains Health Catalyst (NASDAQ:HCAT) with a Neutral and lowers the price target from $4 to $3.
Cantor Fitzgerald analyst Sarah James maintains Health Catalyst (NASDAQ:HCAT) with a Neutral and lowers the price target from $4 to $3.